Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that Frances Hendry has joined CRA as a Vice President in the Life Sciences Practice.

“I am pleased to welcome Frances to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “She is an experienced consultant with a background in managing high-performing teams to deliver meaningful business results for life sciences clients.”

“Frances is an accomplished team leader with expertise in helping pharmaceutical companies bring new products to market and optimize their product portfolios,” said Dr. Gregory K. Bell, Group Vice President and Life Sciences Practice Leader. “Moreover, she shares our approach to building strong, trusted client relationships. We look forward to working with her and leveraging her strengths across our engagements.”

Prior to joining CRA, Ms. Hendry was Vice President of a large healthcare consulting and advisory firm specializing in strategy, policy, and data analysis. Her responsibilities included client relationship management, key account growth, and business development. Before that, she held progressively senior roles at a U.K. marketing consultancy focused on healthcare and pharmaceuticals.

Ms. Hendry has an MA in Business Management from Glasgow University, an MSC in Marketing from Edinburgh Napier University, and a Chartered Institute of Marketing (CIM) Postgraduate Diploma from Cambridge Marketing College.

About CRA’s Life Sciences Practice

CRA’s Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates^® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Frances Hendry and the strengthening of CRA’s Life Sciences Practice, and any future business and outcomes Ms. Hendry may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250923968838/en/